Mar 3, 2016
Prostate Cancer is the most frequently diagnosed form of male cancer in the USA. It is estimated that 233,000 new cases and 29,480 deaths may occur due to prostate cancer this year in the USA. Currently available diagnostic methods do not have major impact on disease out-come, highlighting the urgent need for new approaches for diagnosis and prognosis.
The discovery of micro-RNAs (miRNAs) have enhanced our understanding of cancer biology. miRNAs are small, non-coding RNAs that regulate gene expression and play important role in Carcinogenesis and metastasis. In a recent study researchers at BioGenex profiled expression of miRNAs in different grades of prostate cancer using a novel, high-throughput, automated, in situ hybridization (ISH) technique. The finding demonstrated deregulation of miR-17 and miR-125b in high-grade prostate cancer and an increase in miR-205 expression in benign prostate hyperplasia. These results show that miRNA-ISH can be used for better diagnosis, staging and prognosis of the cancer and may be developed as tool for routine application to improve disease-outcome.
The study was conducted using BioGenex Xmatrx Infinity automated staining platform and miRNA ISH protocols, BioGenex miRNA probes and BioGenex miRNA-ISH detection system. This Research was showcased in 2015 USCAP Annual meeting.
For more details click here
BioGenex designs, develops, and commercializes advanced fully-automated molecular pathology systems for cancer diagnosis, prognosis, personalized medicine, and life science research. The recent introduction of our eFISHency integrated workflow solution for FISH laboratories and miRNA system for characterization of CUP and for undifferentiated tumors is a game changer that has no rival in the industry. Our fully-automated molecular pathology workstations are the most advanced system globally. Our customer focused approach, with premier after sales support and excellent technical service, provides the best in class customer care. Our spirit of innovation drives us to deliver cutting edge technology, years ahead of our competition, and the finest systems for life Science research and diagnostics.